Tempest Therapeutics (TPST)
NASDAQ:TPST
Top Page
Tempest Therapeutics
(NASDAQ:TPST)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-3.85% Downside)
Action:ReiteratedDate:03/31/26
The score is weighed down primarily by weak financial fundamentals (pre-revenue losses, cash burn history, and a weaker 2025 balance sheet) and bearish technicals (downtrend with negative momentum). Positive corporate events—especially encouraging early clinical data and partner-supported development—provide some offset, but valuation support is limited due to ongoing losses and no dividend.
Positive Factors
Clinical efficacy: TPST-2003
Consistently high response rates and favorable safety for TPST-2003 strengthen the drug’s clinical hypothesis and reduce execution risk for a registrational program. Durable strong early efficacy can accelerate regulatory discussions, attract partners, and materially improve long-term commercial prospects.
Negative Factors
Pre-revenue cash burn
Persistent negative operating and free cash flow means ongoing dependence on external financing or partners to fund development. Without product revenue, continued cash burn creates structural financing risk, potential dilution, and constrains the company’s ability to sustain or expand programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy: TPST-2003
Consistently high response rates and favorable safety for TPST-2003 strengthen the drug’s clinical hypothesis and reduce execution risk for a registrational program. Durable strong early efficacy can accelerate regulatory discussions, attract partners, and materially improve long-term commercial prospects.
Read all positive factors
Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.38M
Dividend YieldN/A
Average Volume (3M)50.79K
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue GrowthN/A
EPS Growth49.43%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding14,344,034
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.18
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$11.00Price Target Upside605.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Tempest Therapeutics Business Overview & Revenue Model
Company Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, an...
How the Company Makes Money
Tempest Therapeutics does not primarily generate recurring revenue from marketed products because it is a clinical-stage company; its business model is centered on research and development of drug candidates with the goal of creating value through...
Tempest Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -389.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M |
| Net Income | -26.26M | -41.84M | -29.49M | -35.71M | -28.30M |
Balance Sheet | |||||
| Total Assets | 16.93M | 41.49M | 51.60M | 46.09M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 7.71M | 30.27M | 39.23M | 31.23M | 51.83M |
| Total Debt | 8.14M | 15.37M | 20.66M | 22.11M | 18.54M |
| Total Liabilities | 10.26M | 22.36M | 24.84M | 27.98M | 37.12M |
| Stockholders Equity | 6.67M | 19.13M | 26.77M | 18.11M | 36.12M |
Cash Flow | |||||
| Free Cash Flow | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M |
| Operating Cash Flow | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M |
| Investing Cash Flow | 0.00 | -435.00K | -170.00K | -562.00K | -97.00K |
| Financing Cash Flow | 4.26M | 24.50M | 35.60M | 11.40M | 59.06M |
Tempest Therapeutics Technical Analysis
Negative
1.56
Price Trends
2.23
Negative
3.01
Negative
6.05
Negative
Market Momentum
-0.22
Positive
29.73
Positive
15.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.23, and below the 200-day MA of 6.05, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 29.73 is Positive, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.
Tempest Therapeutics Risk Analysis
Tempest Therapeutics disclosed 66 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tempest Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $22.38M | -0.45 | -310.89% | ― | ― | 49.43% | |
46 Neutral | $19.81M | ― | -1041.79% | ― | ― | 1.18% | |
45 Neutral | $51.24M | -0.97 | -258.37% | ― | ― | 29.95% | |
42 Neutral | $36.71M | -1.25 | -208.66% | ― | 11.11% | 20.65% | |
40 Underperform | $10.09M | -3,346.34 | -526.36% | ― | ― | -2.46% |
* Healthcare Sector Average
TPST
Tempest Therapeutics
1.56
-5.59
-78.18%
ATNM
Actinium Pharmaceuticals
1.17
-0.09
-7.14%
PDSB
PDS Biotechnology
0.92
-0.08
-8.20%
LTRN
Lantern Pharma
1.76
-1.18
-40.14%
CALC
CalciMedica
0.64
-0.94
-59.43%
Tempest Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tempest Therapeutics Announces Private Placement Financing Agreement
Positive
Mar 23, 2026
Tempest Therapeutics entered into a securities purchase agreement on March 20, 2026 with two institutional investors and Factor Bioscience for a private placement of 462,964 common shares and pre-funded warrants for up to 462,963 additional shares...
Business Operations and StrategyProduct-Related Announcements
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data
Positive
Feb 25, 2026
On February 25, 2026, Tempest Therapeutics reported interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, an autologous CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma, alongside results from a prior...
Business Operations and Strategy
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline
Positive
Feb 11, 2026
On February 11, 2026, Tempest Therapeutics announced it would post an updated corporate presentation outlining a diversified, partner-funded oncology pipeline spanning discovery through Phase 2, anchored by its CD19/BCMA and CD70/CD70 CAR-T progra...
Business Operations and StrategyExecutive/Board ChangesDividendsM&A TransactionsPrivate Placements and Financing
Tempest Therapeutics Overhauls Leadership and Acquires New Assets
Positive
Feb 6, 2026
On January 20, 2026, Tempest Therapeutics announced that its board set January 30, 2026 as the record date for a warrant dividend, under which shareholders and certain existing warrant holders received in total 6,784,989 warrants, each allowing th...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Tempest Therapeutics Stockholders Extend Rights Plan and Approvals
Positive
Jan 28, 2026
On January 27, 2026, stockholders of Tempest Therapeutics approved an extension of the company’s limited-duration stockholder rights plan, keeping it in place through October 10, 2026, in a move that helps preserve the existing shareholder b...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
Tempest Therapeutics Faces Nasdaq Noncompliance, Plans Annual Meeting
Negative
Jan 9, 2026
Tempest Therapeutics disclosed that on January 8, 2026 it received a notice from Nasdaq’s Listing Qualifications Department stating the company was not in compliance with Nasdaq’s continued listing rules because it failed to hold an an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.